Eprenetapopt-Azacitidine Combo Shows Promise for AML With TP53 Mutations

Eprenetapopt-Azacitidine Combo Shows Promise for AML With TP53 Mutations

286248

Eprenetapopt-Azacitidine Combo Shows Promise for AML With TP53 Mutations

Eprenetapopt (APR-246), Aprea Therapeutics’ lead cancer therapy candidate, was well-tolerated and showed promising clinical activity when given alongside azacitidine to treat patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) with mutations in the tumor suppressor TP53 gene. According to the company, findings from this Phase 1b/2 trial (NCT03072043) support the continuation of a Phase 3 trial (NCT03745716) that is currently assessing the safety and efficacy of the combination therapy in patients with MDS…

You must be logged in to read/download the full post.